allosteric site identification

Altay Therapeutics is a drug discovery company unlocking the therapeutic potential of transcription factor inhibition to address serious, underserved diseases. Its pipeline includes the first oral small molecule inhibitor of DUX4 for facioscapulohumeral muscular dystrophy (FSHD) and a potential best-in-class STAT3 inhibitor with broad potential in cancer and chronic inflammatory diseases. The company has developed a therapeutic area-agnostic drug discovery platform identifying novel allosteric sites to design highly-selective small molecule inhibitors.

Read more

small molecule drug discoverysmall molecule inhibitor designtranscription factor inhibition